AELIX received financing through ACCIÓ Nuclis program

AELIX has received a grant for the project “Development of a therapeutic vaccine for the treatment of the HIV infection” through the Nuclis program of Agencia per a la Competitivitat de l’Empresa, ACCIÓ, that stimulates industrial research and experimental development activities framed in RIS3CAT and PO FEDER Catalunya 2014-2020 financing programs.
By VR | December 20, 2019

AELIX has received a grant for the project “Development of a therapeutic vaccine for the treatment of the HIV infection” through the Nuclis program of Agencia per a la Competitivitat de l’Empresa, ACCIÓ, that stimulates industrial research and experimental development activities framed in RIS3CAT and PO FEDER Catalunya 2014-2020 financing programs.